The financials
BioCryst Pharmaceuticals, Inc. by the numbers
BioCryst Pharmaceuticals, Inc. (BCRX) reported revenue of $218M in Q2 2026 (quarter ended Jun 30, 2026), up 34% from the same quarter a year earlier. That came with a gross margin of 98% and net income of $78M (36% of revenue). For the full year FY2025, revenue was $875M (+94% year on year) and net income $264M. Its largest product in Q2 2026 was ORLADEYO at $158M, 72% of the disclosed total, well ahead of License Revenue And Other Income From Contract With Customer at 27%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $218M | $163M | +34% |
| Gross profit | $214M | $161M | +34% |
| Operating income | $98M | $30M | +231% |
| Net income | $78M | $5.1M | +1442% |
| Diluted EPS | $0.30 | $0.02 | +1400% |
| Product | Revenue | Share |
|---|---|---|
| ORLADEYO | $158M | 72% |
| License Revenue And Other Income From Contract With Customer | $60M | 27% |
| Research And Development Services | $1.2M | 0.6% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $219.5M (+39%)
License Revenue And Other Income From Contract With Customer grew +822% year on yearORLADEYO +0.87% year on year
Segment Latestquarter on quarteryear on year
- ORLADEYO$158.2M$158.2MQoQ +6.6%year on year +0.87%+6.6%+0.87%
- License Revenue And Other Income From Contract With Customer$60.0M$60.0MQoQ -year on year +822%-+822%
- Research And Development Services$1.2M$1.2MQoQ -year on year ---
Drug Manufacturers - Specialty & Generic
Ranks #28 of 29 by Smart Score